(R)-1-((4-((5-Methyl-2-(4-(trifluoromethyl)phenyl)oxazol-4-yl)methoxy)phenyl)sulfonyl)indoline-2-carboxylic acid

Catalog No. :
ACMNTN253
CAS No. :
839673-52-8
Molecular Formula :
C27H21F3N2O6S
Molecular Weight :
558.53

IUPAC Name:(R)-1-((4-((5-methyl-2-(4-(trifluoromethyl)phenyl)oxazol-4-yl)methoxy)phenyl)sulfonyl)indoline-2-carboxylic acid

(R)-1-((4-((5-Methyl-2-(4-(trifluoromethyl)phenyl)oxazol-4-yl)methoxy)phenyl)sulfonyl)indoline-2-carboxylic acid structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1mg97%$67.00Login to see priceInquiryInquiry
5mg97%$157.00Login to see priceInquiryInquiry
10mg97%$235.00Login to see priceInquiryInquiry
25mg97%$391.00Login to see priceInquiryInquiry
50mg97%$557.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(R)-1-((4-((5-Methyl-2-(4-(trifluoromethyl)phenyl)oxazol-4-yl)methoxy)phenyl)sulfonyl)indoline-2-carboxylic acid
IUPAC Name(R)-1-((4-((5-methyl-2-(4-(trifluoromethyl)phenyl)oxazol-4-yl)methoxy)phenyl)sulfonyl)indoline-2-carboxylic acid
Molecular FormulaC27H21F3N2O6S
Molecular Weight558.53
SMILESO=C([C@@H]1N(S(=O)(C2=CC=C(OCC3=C(C)OC(C4=CC=C(C(F)(F)F)C=C4)=N3)C=C2)=O)C5=C(C=CC=C5)C1)O
InChI KeyKVVODNUBDFULSC-XMMPIXPASA-N
Synonymcevoglitazar;LBM 642;LBM642;LBM-642
CAS No.839673-52-8

Synthetic Route by SureRoute

1. ACMNTN253 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACAKBJ617 route compound structure diagram
    ACAKBJ61798167-06-7 In Stock
  4. Then
  5. ACMNTN253 route product structure diagram
    ACMNTN253839673-52-8
Inquiry

2. ACMNTN253 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACMNTN253 route product structure diagram
    ACMNTN253839673-52-8
Inquiry

Comments (0)